Viral Vector Manufacturing Industry, Growth Dynamics, Share Overview and Global

Posted by Shrikant Gadewar on January 29th, 2020

Market Overview:

The global viral vector manufacturing market is expected to exhibit a strong 22.65% CAGR over the forecast period from 2018 to 2023, according to the latest research report from Market Research Future (MRFR). The report forecasts a valuation of USD 319 million for the market by the end of the 2018-2023 forecast period. In current time, gene therapy is one of the preferred treatment options for most chronic diseases, that involves the insertion of a functional copy of a gene into a defective cell. Viral vector methods thus used in effective transfer of therapeutic gene into the target cells. Therefore, numerous factors such as the mounting necessity for a useful mode of disease treatment, rise in the number of clinical trials and increase in the number of gene therapy are likely to drive the growth of the viral vector manufacturing market.

viral vectors and the absence of the appropriate tools are likely to be the key restraints acting against the global Viral Vector Manufacturing Industry over the forecast period. Many companies in the global viral vector manufacturing market are taking steps to counter the difficulties in producing viral vectors and this area is likely to remain a hive of activity in the coming years. This has also resulted in strong growth prospects for companies that can develop effective viral vector manufacturing platforms and systems and sell them to clients in drug discovery applications.

Competitive Analysis:

• Kaneka Eurogentec S.A.
• REGENXBIO Inc
• Cobra Biologics
• Cell and Gene Therapy Catapult
• Brammer Bio
• FinVector Vision Therapies
• uniQure N.V
• Spark Therapeutics Inc
• Oxford BioMedica
• General Electric Company
• Merck KGaA
• Lonza

Segmentation:

• The global viral vector manufacturing market is segmented on the basis of type, disease, application, end use, and region.
• By type, the global viral vector manufacturing market is segmented into retroviral vectors, adenoviral vectors, adeno-associated viral vectors, and other viral vectors. The retroviral vectors segment is further sub-segmented into lentiviral vectors and gamma-retroviral vectors. The retroviral vectors segment holds the largest share in the global viral vector manufacturing market. Retroviruses contain the enzyme reverse transcriptase, which enables easy assimilation into the host DNA. This has driven the demand for retroviral vectors. The adenoviral vectors segment is also expected to exhibit rapid growth over the forecast period.
• By disease, the global viral vector manufacturing market is segmented into cancer, genetic disorders, infectious diseases, and others.
• By application, the market is segmented into gene therapy and vaccinology.
• By end use, the global viral vector manufacturing market is segmented into pharma and biotech companies, research institutes, and others.

Regional Analysis:

The Americas is anticipated to dominate the global viral vector manufacturing market over the forecast period, followed by Europe.